MPM BioImpact is a biotechnology investment firm specializing in managing early-stage venture and private/public impact.
MPM BioImpact has raised $20.0M in total funding. The most recent round was Corporate Round. The last funding was announced in January 2025.
MPM BioImpact's investors include Meiji Seika Pharma.
MPM BioImpact is headquartered in Boston, United States.
MPM BioImpact is a biotechnology investment firm specializing in managing early-stage venture and private/public impact.
MPM BioImpact is at the Corporate Round stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"MPM BioImpact — Funding & Investors." VCBacked, January 10, 2025, https://www.vcbacked.co/company/mpm-bioimpact. Accessed September 30, 2026.
VCBacked. (2025). MPM BioImpact — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/mpm-bioimpact
{{cite web |title=MPM BioImpact — Funding & Investors |url=https://www.vcbacked.co/company/mpm-bioimpact |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated